

John J Nemunaitis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3465285/publications.pdf>

Version: 2024-02-01

80
papers

3,440
citations

172457

29
h-index

155660

55
g-index

122
all docs

122
docs citations

122
times ranked

4350
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor suppressor immune gene therapy to reverse immunotherapy resistance. <i>Cancer Gene Therapy</i> , 2022, 29, 825-834.	4.6	14
2	Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy. <i>Cancer Gene Therapy</i> , 2022, 29, 993-1000.	4.6	4
3	Subclonal landscape of cancer drives resistance to immune therapy. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100507.	1.7	8
4	Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or pascalisib in advanced solid tumors: a phase I study. , 2022, 10, e004223.		6
5	Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. <i>Clinical Cancer Research</i> , 2022, 28, 903-914.	7.0	14
6	Small-cell breast carcinoma with response to atezolizumab: a case report. <i>Immunotherapy</i> , 2022, 14, 669-674.	2.0	6
7	Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2600-2600.	1.6	3
8	Current Ovarian Cancer Maintenance Strategies and Promising New Developments. <i>Journal of Cancer</i> , 2021, 12, 38-53.	2.5	36
9	Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegiloddecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2). <i>Journal of Thoracic Oncology</i> , 2021, 16, 327-333.	1.1	24
10	Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer. <i>Cancer Gene Therapy</i> , 2021, , .	4.6	12
11	Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 645745.	2.8	15
12	The abscopal effect of radiation therapy. <i>Future Oncology</i> , 2021, 17, 1683-1694.	2.4	61
13	Gemogenovatucl-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 676-680.	1.4	22
14	Ovarian Cancer Immunotherapy and Personalized Medicine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6532.	4.1	128
15	BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer. <i>Future Oncology</i> , 2021, 17, 2817-2830.	2.4	7
16	Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacinab in Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1988-1995.	4.1	6
17	Long-Term Follow-Up of Gemogenovatucl-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. <i>Vaccines</i> , 2021, 9, 894.	4.4	9
18	Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6. <i>Vaccines</i> , 2021, 9, 1201.	4.4	4

#	ARTICLE	IF	CITATIONS
19	Gemogenovatucl-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 459-464.	1.4	11
20	Homologous recombination proficiency in ovarian and breast cancer patients. <i>BMC Cancer</i> , 2021, 21, 1154.	2.6	35
21	A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1009-1016.	7.0	56
22	<i>BRCA1/2</i> Mutation Status Impact on Autophagy and Immune Response: Unheralded Target. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa077.	2.9	11
23	Resident Memory T Cells and Their Effect on Cancer. <i>Vaccines</i> , 2020, 8, 562.	4.4	13
24	Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma. <i>Cancer Letters</i> , 2020, 491, 97-107.	7.2	11
25	Relationship of hypothyroidism and immune response to pegylated IL-10/nivolumab. <i>Immunotherapy</i> , 2020, 12, 1041-1046.	2.0	2
26	Gemogenovatucl-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. <i>Lancet Oncology</i> , The, 2020, 21, 1661-1672.	10.7	69
27	FDA efficiency for approval process of COVID-19 therapeutics. <i>Infectious Agents and Cancer</i> , 2020, 15, 73.	2.6	8
28	Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil [®] in frontline maintenance. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100648.	0.6	15
29	Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. <i>Blood Advances</i> , 2020, 4, 1917-1926.	5.2	51
30	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise. <i>Future Virology</i> , 2020, 15, 381-395.	1.8	7
31	First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1824-1835.	1.6	102
32	PIK3CA gene aberrancy and role in targeted therapy of solid malignancies. <i>Cancer Gene Therapy</i> , 2020, 27, 634-644.	4.6	22
33	TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. <i>Cancer Gene Therapy</i> , 2020, 27, 841-853.	4.6	94
34	A phase I combination study of vigil and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in <i>BRCA1/2</i> -wt patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3002-3002.	1.6	9
35	Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL) <i>Tj ETQq1 1 0.784314 rgBT /Over</i> <i>Clinical Oncology</i> , 2020, 38, 6017-6017.	1.6	4
36	Vigil: Personalized Immunotherapy Generating Systemic Cytotoxic T Cell Response. <i>Cancer Science & Research</i> , 2020, 3, .	0.2	5

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.. Journal of Clinical Oncology, 2020, 38, 3606-3606.	1.6	7
38	Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience. Oncology, 2019, 97, 59-74.	1.9	13
39	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. Journal of Thoracic Oncology, 2019, 14, 1794-1806.	1.1	69
40	Interleukin 10-Mediated Response and Correlated Anemia in a Patient with Advanced Non-Small Cell Lung Carcinoma. Case Reports in Oncology, 2019, 12, 297-303.	0.7	4
41	BIRC5 is a target for molecular imaging and detection of human pancreatic cancer. Cancer Letters, 2019, 457, 10-19.	7.2	16
42	<p>First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy</p>. Cancer Management and Research, 2019, Volume 11, 10463-10476.	1.9	56
43	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma. JAMA Oncology, 2019, 5, 351.	7.1	127
44	Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 12.		67
45	Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability"high (MSI-H) tumors.. Journal of Clinical Oncology, 2019, 37, 670-670.	1.6	24
46	A phase II, multicenter, single-arm trial of CV301 plus atezolizumab (Atezo) in locally advanced (unresectable) or metastatic urothelial cancer (UC).. Journal of Clinical Oncology, 2019, 37, TPS494-TPS494.	1.6	0
47	A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. Clinical Cancer Research, 2018, 24, 2285-2293.	7.0	49
48	KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex. PLoS ONE, 2018, 13, e0193644.	2.5	10
49	Randomized, double"blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. Cancer Medicine, 2018, 7, 5382-5393.	2.8	32
50	Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. JCI Insight, 2018, 3, .	5.0	44
51	Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities.. Journal of Clinical Oncology, 2018, 36, 2584-2584.	1.6	2
52	Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.. Journal of Clinical Oncology, 2018, 36, 4032-4032.	1.6	4
53	Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).. Journal of Clinical Oncology, 2018, 36, 4123-4123.	1.6	64
54	Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).. Journal of Clinical Oncology, 2018, 36, 8517-8517.	1.6	19

#	ARTICLE	IF	CITATIONS
55	Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).. Journal of Clinical Oncology, 2018, 36, 8518-8518.	1.6	29
56	Phase 1b study of avelumab in advanced previously treated mesothelioma: long-term follow-up from JAVELIN Solid Tumor.. Journal of Clinical Oncology, 2018, 36, 8563-8563.	1.6	4
57	Phase 1b results of avelumab in patients (pts) with previously treated metastatic melanoma enrolled in the JAVELIN Solid Tumor trial, including updated subgroup analyses.. Journal of Clinical Oncology, 2018, 36, e21531-e21531.	1.6	0
58	Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous Delivery. Toxicological Sciences, 2017, 155, 400-408.	3.1	8
59	Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy. Journal of Pediatric Hematology/Oncology, 2017, 39, e183-e186.	0.6	11
60	Harnessing the immune response to target tumors. F1000Research, 2017, 6, 710.	1.6	2
61	Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. Gynecologic Oncology, 2016, 143, 504-510.	1.4	77
62	Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma. Molecular Therapy, 2016, 24, 1412-1422.	8.2	34
63	Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma. Molecular Therapy, 2016, 24, 1478-1483.	8.2	73
64	Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma. Biomedical Genetics and Genomics, 2016, 1, .	0.1	8
65	Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer. Molecular Therapy, 2015, 23, 1123-1130.	8.2	19
66	Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma. Molecular Therapy, 2015, 23, 1103-1109.	8.2	45
67	Shedding New Light on the Use of Imaging Technology for Glioblastoma Tumor Resection. Molecular Therapy, 2015, 23, 1136-1137.	8.2	2
68	Summary of bi-shRNA^ffurin</sup>/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG^fC) in Advanced Cancer of the Liver. Oncology, 2014, 87, 21-29.	1.9	46
69	Bifunctional Short Hairpin RNA (bi-shRNA): Design and Pathway to Clinical Application. Methods in Molecular Biology, 2013, 942, 259-278.	0.9	9
70	Tp53 Gene Therapy for Cancer Treatment and Prevention. , 2013, , 189-208.		5
71	Phase I Trial of bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell Vaccine (FANG) in Advanced Cancer. Molecular Therapy, 2012, 20, 679-686.	8.2	167
72	A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2012, 188, 2391-2397.	0.4	181

#	ARTICLE	IF	CITATIONS
73	Phase I Trial of TGF- β 2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine. <i>Clinical Cancer Research</i> , 2011, 17, 183-192.	7.0	48
74	FANG Vaccine: Autologous Tumor Cell Vaccine Genetically Modified to Express GM-CSF and Block Production of Furin. <i>BioProcessing: Advances and Trends in Biological Product Development</i> , 2010, 8, 4-14.	0.1	27
75	Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor- β Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5763-5771.	1.6	540
76	Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2009, 15, 7719-7725.	7.0	87
77	TAG Vaccine: Autologous Tumor Vaccine Genetically Modified to Express GM-CSF and Block Production of TGFB2 (part 2). <i>BioProcessing: Advances and Trends in Biological Product Development</i> , 2009, 8, 38-44.	0.1	6
78	p53 therapy in a patient with Li-Fraumeni syndrome. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1478-1482.	4.1	60
79	Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4721-4730.	1.6	335
80	Vaccines in cancer: GVAX [®] , a GM-CSF gene vaccine. <i>Expert Review of Vaccines</i> , 2005, 4, 259-274.	4.4	97